At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 117 enrolled
Drug / intervention
PF-03187207 +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2, 28-Day Parallel-Group, Double-Masked, Dose Finding Study Comparing The Safety And Efficacy Of PF-03187207 To Latanoprost In Patients With Primary Open Angle Glaucoma Or Ocular Hypertension.
In Brief
A Phase 2 clinical trial evaluating PF-03187207, Latanoprost 0.005%, and 2 other interventions for Primary Open Angle Glaucoma and Ocular Hypertension. Completed, enrolled 117 participants across 13 sites.
Detailed Summary
To investigate dose response, safety and efficacy of PF-03187207 in patients with primary open-angle glaucoma or ocular hypertension
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPrimary Open Angle Glaucoma, Ocular Hypertension
CountriesJapan
Collaborators--
Timeline
Phase 2CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartDec 2007
First PostedJan 2008
Primary CompletionJun 2008
TodayJul 2026
First PostedJan 16, 2008
Enrollment StartDec 1, 2007
Primary CompletionJun 1, 2008
TodayJul 2, 2026
Enrollment to primary: 6 monthsPosted 18.5 years ago
Interventions
PF-03187207drug
Latanoprost 0.005%drug
PF-03187207 Vehicledrug
One drop in study eye once daily for the first 28 days to all subjects, followed by 28 days in combination with PF-03187207.
Latanoprost Vehicledrug